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In CF, nutritional status inﬂuences pulmonary prognosis and survival. After neonatal
screening, great attention is given to the attainment of optimal growth. The high
prevalence of food intake disorders in CF has led our team to investigate the concept
of senso-dysorality. This discipline covers all types of oral feeding difﬁculties. The
senso-motor disorders of orality (dysorality) are related to the exaggeration of the
physiological oral gag reﬂex.
Methods: We conducted a prospective mono-centric study on the prevalence
of dysorality in paediatric CF patients. Moreover, we evaluated the impact of
its management on the quality of life (QOL), food intake and somatic growth.
Initial assessment and subsequent monitoring were performed by a dietician and a
psychologist in collaboration with a gastroenterologist. The rehabilitation program
of the whole oral cavity was performed by speech and language therapists (SLT).
Results: 40% (61/153) of children presented with food intake difﬁculties, 24%
(36/153) of children with true senso-dysorality. The latter was noted in 90%
(9/10) of patients undergoing enteral feeding (gastrostomy). Multidisciplinary
organic, sensory, psychological and nutritional management has been performed
in 52.8% (19/36) patients with dysorality. Better appetite was observed in 68.4%
(13/19) of cases, improved tolerance to diverse meal textures/consistence in 68.4%
(13/19), more serene family meals in 63.2% (12/19) and signiﬁcant weight gain in
68.2% (13/19).
Conclusion: This innovative multidisciplinary approach improves QOL and nutri-
tional status in 2/3 of CFpatients presenting with dysorality.
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Background: Individuals with CF are predisposed to low bone mineral density
(BMD), as raised resorption and reduced formation leads to bone loss. Bis-
phosphonates are often used to inhibit osteoclasts and preserve bone structure.
If used in cases without elevated resorption, these may lead to oversupression
of osteoclasts and bone turnover, resulting in atypical fractures. High plasma
C-terminal telopeptide of type 1 collagen (CTX) reﬂects raised osteoclast activity.
This study analysed CTX levels alongside BMD in adults with CF.
Methods: CTX levels (0.1−0.5mg/l) were assessed at annual screen. BMD was
measured via dual energy x-ray absorptiometry (DEXA) scans, with spinal and
neck of femur scores recorded. Reduced BMD scores at one or both sites were
categorised as osteopenic or osteoporotic values.
Results: 53 patients had CTX levels and BMD assessed. 15 had normal BMD
(NBMD), 24 osteopenic and 14 osteoporotic values. Raised CTX levels were seen
amongst 2 (13%), 6 (25%) and 3 (21%) patients respectively and greatest with
osteopenic (median 0.39mg/l) compared with NBMD (0.29mg/l) and osteoporotic
(0.23mg/l) groups. 7 patients were already taking oral bisphosphonates due to
continuous glucocorticoid treatment, 4 (57%) of these had CTX values <0.1 (range
0.02–0.08mg/l).
Conclusions: The majority of patients (79%) had CTX values within the normal
range, suggesting normal osteoclastic activity. With such patients, bisphosphonates
may have a detrimental effect on bone status. Bone turnover markers such as CTX
may be valuable in selecting and monitoring efﬁcacy of bone treatments.
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Achieving vitamin D sufﬁciency in adults with cystic ﬁbrosis (CF) can be a
challenge due to multiple factors. In the UK production of vitamin D from sunlight
is limited to between April and October. We instigated a change in practice assessing
the vitamin D status of patients during the winter months and compared the
vitamin D status of the clinic and supplementation to a previous year. June 2008–
May 2009, 210 levels were measured on 178 adult CF patients, 16 with pancreatic
sufﬁciency (ps). Mean serum vitamin D level (25-hydroxyvitamin D) = 61.8 nmol/L,
median monthly levels were highest in September at 80.5 nmol/L and lowest in
February at 34.9 nmol/L. 46% (97/210) levels were measured between April and
October. Patients achieving levels >75 nmol/L = 33% (70/210), 50−75 nmol/L =
31% (65/210), 30−50 nmol/L = 20% (43/210), 15−30 nmol/L = 11% (23/210) and
<15 nmol/L = 4% (9/210). Median oral vitamin D supplementation was 900 iu
of vitamin D June 2011–May 2012, 445 levels were measured on 276 patients,
20 with ps. Mean serum vitamin D level 59.9 nmol/L, median monthly levels
were highest in September at 69.4 nmol/L and lowest in December at 50.4 nmol/L.
31% (138/445) levels measured between April and October. Patients achieving lev-
els >75 nmol/L = 27% (120/445), 50−75 nmol/L = 33% (145/445), 30−50 nmol/L =
24% (110/445), 15−30 nmol/L = 11% (48/445), <15 nmol/L = 5% (22/445). Median
oral vitamin D supplementation was 1300 iu. Assessing vitamin D status during
November–March identiﬁed 7% more suboptimal levels in our clinic. This change
in practice has improved the vitamin D status of our clinic population in the winter
months, and increased our level of vitamin D supplementation.
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Vitamin D is a vitamin of great interest in Cystic Fibrosis (CF) because of its role
in bone mineralisation. Insufﬁcient levels are widely reported. Previously published
25(OH)D results for our cohort of 286 patients (pts) indicated mean 25(OH)D levels
of 79.3 nmol/L ±23.7. This optimal level was obtained through a protocol where
double doses of D3 were given during winter months, deﬁned as the period from
Nov. to Apr.
Objective: Determine if pts on a lung transplant list with severe lung disease have
more difﬁculty obtaining optimal 25(OH)D levels.
Methods: A 1 year retrospective analysis was conducted in Jan. 2013. Of the 312
CF pts followed, 24 are on the lung transplant list: 62.5% female (F), median age
30, 37.5% male (M), median age 37. Median BMI was 21 for F and 24 for M.
Median predicted FEV1 % was 34 for M and 30 for F. 19 pts received double doses
of D3 during winter.
Results: Mean 25(OH)D values were 88.0 nmol/L (±26.7), F having higher levels
(96.3 nmol/L ±29.0) than M (74.1 nmol/L ±14.7). 16 pts (66.7%) M + F showed
optimal levels (75 nmol/L). Insufﬁciency levels were observed for 5 M and 2 F,
while 1 F showed deﬁciency level (40 nmol/L). Poor compliance was observed in
a number of pts where optimal levels were not obtained.
Conclusion: Severe CF disease klatis not an obstacle in attaining optimal 25(OH)D
levels in our cohort awaiting lung transplant. Female patients had better results
for 25(OH)D levels than male patients. Double doses of vitamin D3 during the
winter months, in conjunction with close nutritional monitoring by CF dedicated
dietician, resulted in a signiﬁcant percentage of CF patients attaining optimal levels
of 25(OH)D.
